Skip to main content

The Immunotherapeutic Effect of Fe3O4 Nanoparticles as Adjuvants on Mice H22 Live Cancer

Buy Article:

$113.00 plus tax (Refund Policy)


The aim of this paper is to prepare Fe3O4 nanoparticles and study its immunotherapeutic effect as adjuvants on mice H22 live cancer. The Fe3O4 nanoparticles were prepared by chemical coprecipitation route. Transmission electron microscopy (TEM), X-ray diffraction (XRD), Energy Dispersive Analysis (EDS) were used to characterize Fe3O4 nanoparticles. The Fe3O4 nanoparticles were compared with the common alum adjuvants for its ability to induce immunity to inhibit tumor growth rate by prophylactic and therapeutic studies. Results indicated that Fe3O4 nanopaticles adsorbed autovaccine took great advantages over the common alum adjuvants after subcutaneous injection, raised the mass inhibitory rate of tumor, boosted the activity of cytotoxicity and enhanced the level of IFN-γ cytokine. Thus, we concluded that Fe3O4 nanoparticles as adjuvants had great potential for enhancing anti-tumor immune response.


Document Type: Research Article


Publication date: 2010-01-01

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more